The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs

References

• Baumgartel C. Myths, questions, facts about generic drugs in the EU. GaBI Journal 2012;1:34-8
   Google Scholar
• Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26
   PubMed Web of Science ®Google Scholar
• Anis AH, Guh DP, Woolcott J. Lowering generic drug prices: less regulation equals more competition. Med Care 2003;41(1):135-41
   PubMed Web of Science ®Google Scholar
• Dalen DM, Strøm S, Haabeth T. Price regulation and generic competition in the pharmaceutical market. Eur J Health Econ 2006;7:208-4
   PubMedGoogle Scholar
• Dylst P, Vulto A, Simoens S. Analysis of European policy towards generic medicines. GaBi J 2014;3(1):34-5
   Google Scholar
• Puig-Junoy J. Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics 2010.28(8):649-63. Available from: www.ncbi.nlm.nih.gov/pubmed/20515079
   Google Scholar
• Simoens S. A review of generic medicine pricing in Europe. GaBi J 2012;1(1):8-12
   Google Scholar
• Dylst P, Simoens S. Does the market share of generic medicines influence the price level?: a European analysis. Pharmacoeconomics 2011;29(10):875-82
   PubMed Web of Science ®Google Scholar
• Fischer MA, Avorn J. Economic Consequences of Underuse of Generic Drugs: Evidence from Medicaid and Implications for Prescription Drug Benefit Plans. Health Serv Res 2003;38(4):1051-63
   PubMed Web of Science ®Google Scholar
• Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med 2005;142:891-7
   PubMed Web of Science ®Google Scholar
• Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin 2007;23:105-16
   PubMed Web of Science ®Google Scholar
• Seely E, Kanavos P. Generic medicines from a societal perspective: savings for health care system? Eurohealth 2008;14(2):18-22
   Google Scholar
• Vogler S, Zimmerman N. How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. GaBi J 2013;2(2):65-75
   Google Scholar
• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharm Out 2010;10(6):707-22
   Web of Science ®Google Scholar
• Simoens S, De Coster S. Sustaining Generic Medicines Markets in Europe. Res Center Pharmaceut Care Pharmacoecon 2006. Available from: http://www.assogenerici.org/articolihome/simoens-report_2006-04.pdf
   Google Scholar
• Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharm Out 2013;13(1):59-72
   PubMed Web of Science ®Google Scholar
• Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries – an overview. GaBi J 2012;1(2):93-100
   Google Scholar
• Cameron A Laing R. Cost savings of switching private sector consumption from originator brand medicines to generic equivalents. Available from: www.who.int/healthsystems/topics/financing/healthreport/35MedicineCostSavings.pdf
   Google Scholar
• Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU Economic Papers 461 | September. 2012. Available from: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf
   Google Scholar
• Ministry of Health and Welfare (MOHW). New drug price policy will be implemented in April. 2012. Press Release 2012. Available from: http://www.mw.go.kr/front_new/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=183&CONT_SEQ=267283
   Google Scholar
• National Health Insurance Statistical Yearbook 2013, NHIS and HIRA. Available from: www.nhis.or.kr/menu/boardRetriveMenuSet.xx?menuId=F3321 [Last accessed 17 October 2014]
   Google Scholar
• OECD (2014), “Pharmaceutical expenditure”, Health: Key Tables from OECD, No. 7. DOI: 10.1787/pharmexp-table-2014-1-en [ Last accessed 22 October 2014]
   Google Scholar
• Health Insurance Review & Assessment Service (HIRA). Statistical indicators for medical costs. Available from: www.hira.or.kr/dummy.do?pgmid=HIRAA020045030000&cmsurl=/cms/open/04/02/03/03/stats_surface.html [Last accessed 10 October 2014]
   Google Scholar
• Ministry of Health and Welfare (MOHW), Enforcement Regulations of National Health Insurance Raw, No. 258, Amended on September 1, 2014
   Google Scholar
• Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Inter Med 2006;166(3):332-7
   PubMed Web of Science ®Google Scholar
• Barbui C, Conti V. Adherence to generic v. brand antidepressant treatment and the key role of health system factors. Epidemiol Psychiatr Sci 2015;24(1):23-6
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Welfare (MOHW), Pricing and Re-pricing Standards for Reimbursable Pharmaceuticals, Notification No. 2010-79, September 30; 2010
   Google Scholar
• Kwon SM, Kim S, Kim T, et al. International comparison of generic prices, National Health Insurance Service & Health Insurance Review & Assessment Service Joint Research, 2010. Korean
   Google Scholar
• Ministry of Health and Welfare (MOHW), Statistics for reimbursable medicines, 2010
   Google Scholar
• Ministry of Health and Welfare (MOHW), Incentives for substituting low cost bioequivalent generics, 2001
   Google Scholar
• Ministry of Health and Welfare (MOHW), Standards of the Incentives for Providers, Notification No. 2013-173, 2013
   Google Scholar
• Shin ST. The problems of nonproprietary names prescription. J Korean Med Assoc 2008;51(2):98-102
   Web of Science ®Google Scholar
• Choi SE, Hwang IK, Lee HY, et al. Study on the improvement of pharmacy payment system, The national health insurance service & the korean pharmaceutical association joint research. 2012
   Google Scholar
• National Health Insurance Service (NHIS). Internal data 2013
   Google Scholar
• Wooldridge JM. Econometric analysis of cross section and panel data. The MIT Press; Cambridge: 2002
   Google Scholar
• Aronsson T, Bergman MA, Rudholm N. The impact of generic drug competition on brand name market shares – evidence from micro data. Rev Ind Organ 2001;19:425-35
   Web of Science ®Google Scholar
• Hurwitz MA, Caves RE. Persuasion or information-promotion and the shares of brand name and generic pharmaceuticals. J Law Econ 1988;31:299
   Web of Science ®Google Scholar
• Grabowski H, Vernon J. Brand loyalty; entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ 1992;35(2):195-8
   Web of Science ®Google Scholar
• Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy 2004;68:47-54
   PubMed Web of Science ®Google Scholar
• Magazzini L, Pammolli F, Riccaboni M. Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure. Eur J Health Econ 2004;5(2):175-82
   PubMedGoogle Scholar
• Hausman J. Specification tests in econometrics. Econometrica 1978;46:1251-71
   Web of Science ®Google Scholar
• Min IS, Choi PS. Stata panel data analysis. 1st edition. Jiphil Publication; Seoul: 2012
   Google Scholar
• Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012;1(6):527-38
   PubMed Web of Science ®Google Scholar
• Heinze G, Hronsky M, Reichardt B, et al. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study. Appl Health Econ Health Policy 2014;13(2):193-205
   Google Scholar
• Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value health 2012;15(5):664-73
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A, et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2009;9(5):475-84
   PubMedGoogle Scholar
• Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9(1):65-83
   PubMedGoogle Scholar
• Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):469-82
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106
   PubMed Web of Science ®Google Scholar
• Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res 2011;11(3):343-9
   PubMed Web of Science ®Google Scholar
• Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy 2010;8(1):7-24
   PubMedGoogle Scholar
• Veronin M. Should we have concerns with generic versus brand antimicrobial drugs? A Rev Issues JPHSR 2011;2:135-50
   Google Scholar
• Corrao G, Soranna D, Arfe A, et al. Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. Eur J Inter Med 2014;25(8):745-50
   PubMed Web of Science ®Google Scholar
• Corrao G, Soranna D, Merlino L, Mancia G. Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study. Eur J Clin Invest 2014;44(10):933-9
   PubMed Web of Science ®Google Scholar